Tyra Biosciences, Inc. - 8-K Filing
Tyra Biosciences reported $383.5 million in cash and equivalents as of March 31, 2026, providing a runway into the second half of 2028. The company incurred first-quarter R&D expenses of $33.5 million (up from $25.0 million YoY) due to clinical trial expansion for dabogratinib in urologic cancers and achondroplasia. It also reported a net loss of $39.3 million compared to $28.1 million in the same period last year. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $TYRA